◆英語タイトル:Medical Research Council - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013326
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Medical Research Council (MRC) is a human health research council that offers medical research programs. The council offers research across medical sciences services, universities and hospitals, centers and institutes. It provides data management, research platform, tools and facilities to generate mouse models of human disease for researchers. MRC funds various research programs, for experimental medicine, informatics, lifelong health and wellbeing, obesity research, population health sciences, regenerative medicine and stem cells and stratified medicine, among others. The council carries out research in universities, hospitals and a network of dedicated establishments in the UK and African countries. MRC is headquartered in Swindon, the UK.
Medical Research Council – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Medical Research Council, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Medical Research Council, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Medical Research Council, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Medical Research Council, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Medical Research Council, Medical Devices Deals, 2011 to YTD 2017 9
Medical Research Council, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Medical Research Council, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 11
Enamine Enters Into Co-Development Agreement With MRC LMB And IOCB For Rhomboid Protease Inhibitors 13
Medical Research Council, Imperial College, King’s College and UCL Form Joint Venture 14
Imperial College London, King’s College London, University College London, Medical Research Council And GSK Form Joint Venture 15
Licensing Agreements 17
Cambridge Research Biochemicals Enters Into Licensing Agreement With Medical Research Council 17
Phosphate Therapeutics Enters Into Licensing Agreement With Medical Research Council For PT20 18
Medical Research Council – Key Competitors 19
Medical Research Council – Key Employees 20
Medical Research Council – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 22
Recent Developments 23
Government and Public Interest 23
Aug 17, 2017: Molecule discovered by MRC researchers on path to drug development in neurodegeneration 23
Aug 17, 2017: MRC researchers win prestigious awards for contribution to neurodegeneration research 24
Jul 10, 2017: Research for health systems improvement will be funded 25
Apr 20, 2017: ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimers and FTD 26
Mar 17, 2017: Oxford BioDynamics announces collaboration to identify biological factors that trigger disease relapses in Rheumatoid Arthritis 27
Mar 02, 2017: Abzena, UCL secure £3.5m grant from MRC for autoimmune therapy research 28
Jan 25, 2017: Zika virus, superbugs and arthritis targeted through £26 million fund 29
Aug 31, 2016: Accumulation of a product of cell metabolism found to be linked with kidney tumour growth 30
May 19, 2016: MRC announces cross-council awards worth nearly £10m to tackle antibiotic resistance 31
May 17, 2016: Psilocybin for treatment-resistant depression 33
Apr 26, 2016: Potential cause of dementia to be investigated with £1m grant 35
Feb 16, 2016: Gene could help identify psychosis risk in cannabis users 36
Feb 15, 2016: Cutting edge medical research ideas receive £23.2m boost 37
Feb 11, 2016: Blocking stress protein relieves chronic pain in mice 38
Feb 03, 2016: MRC launches Rapid Response to fast-track Zika research 39
Jan 27, 2016: Study finds paracetamol use in pregnancy can cut female fertility 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Tables
Medical Research Council, Pharmaceuticals & Healthcare, Key Facts 2
Medical Research Council, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Medical Research Council, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Medical Research Council, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Medical Research Council, Deals By Therapy Area, 2011 to YTD 2017 8
Medical Research Council, Medical Devices Deals, 2011 to YTD 2017 9
Medical Research Council, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 11
Enamine Enters Into Co-Development Agreement With MRC LMB And IOCB For Rhomboid Protease Inhibitors 13
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 14
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 15
Cambridge Research Biochemicals Enters Into Licensing Agreement With Medical Research Council 17
Phosphate Therapeutics Enters Into Licensing Agreement With Medical Research Council For PT20 18
Medical Research Council, Key Competitors 19
Medical Research Council, Key Employees 20
Medical Research Council, Other Locations 21
Medical Research Council, Subsidiaries 21
Medical Research Council, Joint Venture 22